Last reviewed · How we verify
NCT06137430
Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure
trial testing Sodium-glucose cotransporter 2 inhibitor in SGLT2 Inhibitiors Remodeling Effect in 98 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 98 |
| Start date | 1 December 2023 |
| Primary completion | 1 December 2024 |
| Estimated completion | 31 December 2024 |
Drugs / interventions tested
- Sodium-glucose cotransporter 2 inhibitor — full drug profile →
Conditions studied
- SGLT2 Inhibitiors Remodeling Effect — all drugs for SGLT2 Inhibitiors Remodeling Effect →
- Chronic Heart Disease — all drugs for Chronic Heart Disease →
Sponsor
Assiut University
Who can join
Adults 18 to 75, any sex, with SGLT2 Inhibitiors Remodeling Effect or Chronic Heart Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy of SGLT2 inhibitors on left ventricular global longitudinal strain and diastology parameters among diabetic and non-diabetic patients with chronic heart failure
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06137430
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sodium-glucose cotransporter 2 inhibitor
Trials testing the same drug.
- NCT06140251 — Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure · unknown
- NCT04662723 — Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. · Phase 4 · recruiting
- NCT05214573 — Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk · completed
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06137430 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06137430.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing